We are pioneering the development and commercialization of a proprietary imaging system for the early detection and diagnosis of skin cancer. Our product, the SkinScan 650, is a non-invasive, painless, point-of-care system that will assist physicians in detecting different kinds of skin nevi, tumors, lesions and cancers.
Our technologies are the foundation for the development of this non-invasive, in-vivo skin cancer detection and delineation system. This diagnostic tool will deliver significant clinical impact through improved patient outcomes.
Why it is needed
One of the most critical decisions a physician can make is whether a mark on a patient’s skin could be cancerous. Currently dermatologists and other primary care physicians primarily use visual clinical evaluations to diagnose skin cancer.
Physicians assess pigmented skin lesions using the “ABCDE” criteria – asymmetry, border irregularity, color variation, diameter and evolving. Depending on the outcome of the visual examination, the physician resorts to a biopsy to confirm the presence of cancerous tissue.
However, the process is subjective and leads to misdiagnosis. This, in turn, leads to unnecessary biopsies of benign lesions – as high as 40:1 for dermatologists and 80:1 for primary care physicians.
Even with the aid of a dermascope the risk of misdiagnosis in unnecessarily high. And in many cases, further analysis through biopsy is still required to confirm the presence of cancerous tissue.
Therefore, there is a distinct need for a safe, quick, painless, non-intrusive technology to detect skin cancer.